Literature DB >> 33718397

Unsupervised Clustering Reveals Sarcoidosis Phenotypes Marked by a Reduction in Lymphocytes Relate to Increased Inflammatory Activity on 18FDG-PET/CT.

Christen Vagts1, Christian Ascoli1, Dustin R Fraidenburg1, Robert P Baughman2, Yue Huang1, Russell Edafetanure-Ibeh1, Samreen Ahmed3, Benjamin Levin4,5, Yang Lu6, David L Perkins7, Patricia W Finn1, Nadera J Sweiss1,3.   

Abstract

Introduction: Sarcoidosis is a T-helper cell mediated disease characterized by granulomatous inflammation. We posited that unsupervised clustering of various features in sarcoidosis would establish phenotypes associated with inflammatory activity measured by 18FDG-PET/CT. Our goal was to identify unique features capable of distinguishing clusters and subsequently examine the relationship with FDG avidity to substantiate their potential use as markers for sarcoidosis inflammation.
Methods: We performed a retrospective study of a diverse, but primarily African American, cohort of 58 subjects with biopsy proven sarcoidosis followed at the University of Illinois Bernie Mac Sarcoidosis Center and Center for Lung Health who underwent 18FDG-PET/CT scan. Demographic, therapeutic, radiographic, and laboratory data were utilized in unsupervised cluster analysis to identify sarcoidosis phenotypes. The association between clusters, their defining features, and quantitative measurements on 18FDG-PET/CT was determined. The relevance of these features as markers of 18FDG-PET/CT inflammatory activity was also investigated.
Results: Clustering determined three distinct phenotypes: (1) a predominantly African American cluster with chronic, quiescent disease, (2) a predominantly African American cluster with elevated conventional inflammatory markers, advanced pulmonary disease and extrathoracic involvement, and (3) a predominantly Caucasian cluster characterized by reduced lymphocyte counts and acute disease. In contrast to the chronic quiescent cluster, Clusters 2 and 3 were defined by significantly greater FDG avidity on 18FDG-PET/CT. Despite similarly increased inflammatory activity on 18FDG-PET/CT, Clusters 2, and 3 differed with regards to extrathoracic FDG avidity and circulating lymphocyte profiles, specifically CD4+ T-cells. Notably, absolute lymphocyte counts and CD4+ T-cell counts were found to predict 18FDG-PET/CT inflammatory activity by receiver operating curve analysis with a 69.2 and 73.42% area under the curve, respectively. Conclusions: Utilizing cluster analysis, three distinct phenotypes of sarcoidosis were identified with significant variation in race, disease chronicity, and serologic markers of inflammation. These phenotypes displayed varying levels of circulating inflammatory cells. Additionally, reduction in lymphocytes, specifically CD4+ T-cells, was significantly related to activity on 18FDG-PET/CT. Though future studies are warranted, these findings suggest that peripheral lymphocyte counts may be considered a determinant of sarcoidosis phenotypes and an indicator of active inflammation on 18FDG-PET/CT.
Copyright © 2021 Vagts, Ascoli, Fraidenburg, Baughman, Huang, Edafetanure-Ibeh, Ahmed, Levin, Lu, Perkins, Finn and Sweiss.

Entities:  

Keywords:  18FDG-PET/CT; cluster analysis; immunopathogenesis; lymphopenia; phenotype; sarcoidosis

Year:  2021        PMID: 33718397      PMCID: PMC7943443          DOI: 10.3389/fmed.2021.595077

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  50 in total

1.  The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.

Authors:  Marc A Judson; Ulrich Costabel; Marjolein Drent; Athol Wells; Lisa Maier; Laura Koth; Hidenobu Shigemitsu; Dan A Culver; Jeffrey Gelfand; Dominique Valeyre; Nadera Sweiss; Elliott Crouser; Adam S Morgenthau; Elyse E Lower; Arata Azuma; Mami Ishihara; Shin-Ichiro Morimoto; Tetsuo Tetsuo Yamaguchi; Noriharu Shijubo; Jan C Grutters; Misha Rosenbach; Hui-Ping Li; Paola Rottoli; Yoshikazu Inoue; Antje Prasse; Robert P Baughman; The Wasog Sarcoidosis Organ Assessment Instrument Investigators
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2014-04-18       Impact factor: 0.670

2.  The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-{alpha} therapy.

Authors:  Elliott D Crouser; Gerard Lozanski; Charity C Fox; David W Hauswirth; Rekha Raveendran; Mark W Julian
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

3.  Two novel, severe asthma phenotypes identified during childhood using a clustering approach.

Authors:  Jocelyne Just; Rahele Gouvis-Echraghi; Sarah Rouve; Stephanie Wanin; David Moreau; Isabella Annesi-Maesano
Journal:  Eur Respir J       Date:  2012-01-20       Impact factor: 16.671

4.  Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations.

Authors:  Nadera J Sweiss; Rafah Salloum; Seema Gandhi; Seema Ghandi; Maria-Luisa Alegre; Ray Sawaqed; Maria Badaracco; Kenneth Pursell; David Pitrak; Robert P Baughman; David R Moller; Joe G N Garcia; Timothy B Niewold
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

5.  FDG PET for gauging of sarcoid disease activity.

Authors:  Human Adams; Ruth G Keijsers; Ingrid H E Korenromp; Jan C Grutters
Journal:  Semin Respir Crit Care Med       Date:  2014-07-09       Impact factor: 3.119

Review 6.  Tumor-to-background ratio to predict response to chemotherapy of osteosarcoma better than standard uptake values.

Authors:  Jin-peng He; Yun Hao; Mi Li; Jiang Wang; Feng-jin Guo
Journal:  Orthop Surg       Date:  2014-05       Impact factor: 2.071

7.  Clinical phenotypes and prediction of chronicity in sarcoidosis using cluster analysis in a prospective cohort of 694 patients.

Authors:  Manuel Rubio-Rivas; Xavier Corbella
Journal:  Eur J Intern Med       Date:  2020-04-21       Impact factor: 4.487

8.  The Utility of 18F-FDG PET/CT for Monitoring Response and Predicting Prognosis after Glucocorticoids Therapy for Sarcoidosis.

Authors:  Hengyi Chen; Rongbing Jin; Yubo Wang; Li Li; Kunlin Li; Yong He
Journal:  Biomed Res Int       Date:  2018-03-01       Impact factor: 3.411

9.  Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis.

Authors:  Milou C Schimmelpennink; Adriane D M Vorselaars; Marcel Veltkamp; Ruth G M Keijsers
Journal:  EJNMMI Res       Date:  2019-06-13       Impact factor: 3.138

10.  Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Elliott D Crouser; Lisa A Maier; Kevin C Wilson; Catherine A Bonham; Adam S Morgenthau; Karen C Patterson; Eric Abston; Richard C Bernstein; Ron Blankstein; Edward S Chen; Daniel A Culver; Wonder Drake; Marjolein Drent; Alicia K Gerke; Michael Ghobrial; Praveen Govender; Nabeel Hamzeh; W Ennis James; Marc A Judson; Liz Kellermeyer; Shandra Knight; Laura L Koth; Venerino Poletti; Subha V Raman; Melissa H Tukey; Gloria E Westney; Robert P Baughman
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

View more
  1 in total

Review 1.  The role of PET in the management of sarcoidosis.

Authors:  Robert J Vender; Hamad Aldahham; Rohit Gupta
Journal:  Curr Opin Pulm Med       Date:  2022-07-16       Impact factor: 2.868

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.